CA2364253A1 - Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase - Google Patents

Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase Download PDF

Info

Publication number
CA2364253A1
CA2364253A1 CA002364253A CA2364253A CA2364253A1 CA 2364253 A1 CA2364253 A1 CA 2364253A1 CA 002364253 A CA002364253 A CA 002364253A CA 2364253 A CA2364253 A CA 2364253A CA 2364253 A1 CA2364253 A1 CA 2364253A1
Authority
CA
Canada
Prior art keywords
compound
dihydroxy open
open acid
simvastatin
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002364253A
Other languages
English (en)
Inventor
Richard D. Tillyer
Paul J. Reider
Edward J. J. Grabowski
Feng Xu
Jose M. Vega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2364253A1 publication Critical patent/CA2364253A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des procédés et des compositions pharmaceutiques pour l'inhibition de la HMG-CoA réductase, ainsi que pour le traitement et/ou la réduction du risque de maladies et d'états modifiés par l'inhibition de la HMG-CoA réductase. Lesdits procédés consistent à administrer par voie orale une dose efficace au plan thérapeutique d'un composé choisi parmi une statine d'acide ouvert en dihydroxy, un sel acceptable au plan pharmaceutique ou un ester, dans une forme galénique à effet retard, à un patient ayant besoin dudit traitement, la libération du composé par la forme galénique étant retardée jusqu'à ce que la forme galénique soit passée dans l'estomac.
CA002364253A 1999-03-08 2000-02-02 Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase Abandoned CA2364253A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12322799P 1999-03-08 1999-03-08
US60/123,227 1999-03-08
US26474499A 1999-03-09 1999-03-09
US09/264,744 1999-03-09
PCT/US2000/002626 WO2000053173A1 (fr) 1999-03-08 2000-02-02 Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase

Publications (1)

Publication Number Publication Date
CA2364253A1 true CA2364253A1 (fr) 2000-09-14

Family

ID=26821357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002364253A Abandoned CA2364253A1 (fr) 1999-03-08 2000-02-02 Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase

Country Status (9)

Country Link
EP (1) EP1161236A1 (fr)
JP (2) JP2002538202A (fr)
AR (1) AR022856A1 (fr)
AU (1) AU2866400A (fr)
CA (1) CA2364253A1 (fr)
CO (1) CO5150193A1 (fr)
PE (1) PE20001559A1 (fr)
SV (1) SV2002000036A (fr)
WO (1) WO2000053173A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389973A1 (fr) * 1999-11-04 2001-05-10 Andrx Corporation Methode de traitement de troubles lies au precurseur beta-amyloide
CA2421018A1 (fr) * 2000-09-06 2002-03-14 Merck & Co., Inc. Sel d'acide ouvert dihydroxy de simvastatine
ZA200302507B (en) * 2000-10-12 2004-03-31 Nisaan Chemical Ind Ltd Preventives and remedies for complications of diabetes.
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
HRPK20040255B3 (en) * 2001-08-16 2006-02-28 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1471930B1 (fr) * 2002-01-09 2007-04-11 Crucell Holland B.V. Utilisation de l'erythropoietine pour le traitement preventif ou curatif de l'insuffisance cardiaque
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (fr) 2003-03-07 2008-08-27 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
CA2517572C (fr) 2003-03-07 2011-12-13 Schering Corporation Composes d'azetidinone substitues, leurs formulations et leur utilisation pour traiter l'hypercholesterolemie
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
EP3058089B1 (fr) * 2013-10-18 2018-12-05 Institut National de la Santé et de la Recherche Médicale (INSERM) Petits arn dérivés de rny en tant que biomarqueurs pour des troubles associés à l'athérosclérose
KR20240157129A (ko) * 2017-05-15 2024-10-31 유니버시티 오브 신시내티 심바스타틴의 하나 이상의 대사 산물들을 직접 투여함으로써 무혈관성 연골 조직의 결함들을 치료하기 위한 조성물들 및 방법들
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
WO1997023200A1 (fr) * 1995-12-22 1997-07-03 Kowa Company, Ltd. Composition pharmaceutique stabilisee a l'aide d'un agent de base
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
CO5150193A1 (es) 2002-04-29
AR022856A1 (es) 2002-09-04
JP2002538202A (ja) 2002-11-12
EP1161236A1 (fr) 2001-12-12
AU2866400A (en) 2000-09-28
WO2000053173A1 (fr) 2000-09-14
JP2000256191A (ja) 2000-09-19
SV2002000036A (es) 2002-02-05
PE20001559A1 (es) 2001-01-16

Similar Documents

Publication Publication Date Title
US6569461B1 (en) Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
CA2364253A1 (fr) Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase
AU764048B2 (en) Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
EP1036563A1 (fr) Formulations retard a usage oral de simvastatine sous forme ouverte d'acide dihydroxy, de ses sels ou de ses esters
CN1867322B (zh) 结晶形式的γ-氨基丁酸类似物
AU2002310409B2 (en) Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
AU2010221167B2 (en) Oral dosage forms having a high loading of a gabapentin prodrug
HRP20030104A2 (en) Therapeutic combination
US20030176501A1 (en) Dihydroxy open-acid salt of simvastatin
EP3904335B1 (fr) Dérivé d'acide acétylsalicylique et traitement transdermale et transmucosale des indications associées à l'acide acétylsalicylique
US12208167B1 (en) Coated tablets for pH-dependent release of benzgalantamine
HK1029758A (en) Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
EP2024316B9 (fr) Forme cristalline du leucotriene b4
HK1029786A (en) Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
US9969674B2 (en) MMF-derivatives of ethyleneglycols
ES2281594T3 (es) Procedimiento para la preparacion de adsorbatos de atorvastatina en polvo de flujo libre.
US11795180B2 (en) Formulation of a pan-JAK inhibitor
WO2025147235A1 (fr) Composition d'association à dose fixe d'obicetrapib et d'ézétimibe
JP2008162949A (ja) チアゾリジンジオン化合物を含有する糖尿病治療薬
CN102976996A (zh) 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用

Legal Events

Date Code Title Description
FZDE Dead